A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio Affinity Technologies, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 13,264 shares of BIAF stock, worth $10,611. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,264
Holding current value
$10,611
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$0.88 - $2.18 $11,672 - $28,915
13,264 New
13,264 $12,000
Q3 2022

Nov 14, 2022

BUY
$2.11 - $8.3 $43,430 - $170,838
20,583 New
20,583 $60,000

Others Institutions Holding BIAF

About bioAffinity Technologies, Inc.


  • Ticker BIAF
  • Exchange
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 2,727,580
  • Market Cap $2.18M
  • Description
  • bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...
More about BIAF
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.